Drug, bio-affecting and body treating compositions inventions 08/07

20070202052 - Method for increasing the expression of pulmonary surfactant protein-b: The present invention is directed to a novel method for increasing the expression of pulmonary surfactant protein-B in an infant. The method comprises administration of a therapeutically effective amount of DHA and ARA, alone or in combination with one another, to the infant.... Agent: Richard D. Schmidt Bristol-myers Squibb Company

20070202058 - Compositions for treating gastric reflux: Methods and compositions for treating gastric reflux or the pain associated therewith comprising orally administering therapeutically effective amounts of certain amino acids in a pharmaceutically acceptable composition are described herein.... Agent: Gary Calton

20070202069 - Polymers containing silicone copolyol macromers and personal care compositions containing same: Dimethicone copolyol polymers are synthesized from dimethicone copolyol macromers. Polymers containing the macromer repeating units are useful in a variety of applications including personal care, textile and industrial formulations to deliver softness, lubricity, fixative, humidity resistance, water repellency, gloss, surface modification, and surfactant properties.... Agent: Legal Department Lubrizol Advanced Materials, Inc

20070202091 - Nutraceutical composition and method for promoting the rejuvenation of cells in warm-blooded animals including humans: A nutraceutical composition and method for promoting the rejuvenation of cells in warm-blooded animals including humans employing mitochondrial energy production-inducing agent for inducing the mitochondrial energy production to proceed from a lower energy production state to a higher energy production state and a nutraceutical composition for supporting the metabolic requirements... Agent: Allen R. Kipnes, Esq. Watov & Kipnes, P.C.

20070202039 - Solid-phase preparation of [18f]fluorohaloalkanes: n

20070202040 - Blood clot-targeted nanoparticles: Emulsions comprising nanoparticles formed from high boiling perfluorochemical substances, said particles coated with a lipid/surfactant coating are made target-specific by directly coupling said nanoparticles to a targeting ligand. The nanoparticles may further include biologically active agents, radionuclides, and/or other imaging agents.... Agent: Morrison & Foerster LLP

20070202044 - Antibody therapy: The present invention provides a composition comprising naked humanized, chimeric, and human anti-CEA antibodies and a therapeutic agent, which is useful for treatment of CEA expressing cancers and other diseases, and methods of use in treatment using this composition.... Agent: Faegre & Benson LLP Patent Docketing

20070202041 - Cancerous disease modifying antibodies: The present invention relates to a method for producing cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be... Agent: Mchale & Slavin, P.A.

20070202042 - Cancerous disease modifying antibodies: The present invention relates to a method for producing cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be... Agent: Mchale & Slavin, P.A.

20070202043 - Cytotoxicity mediation of cells evidencing surface expression of trop-2: The present invention relates to a method for producing cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be... Agent: Mchale & Slavin, P.A.

20070202045 - Serum albumin binding peptides for tumor targeting: Peptide ligands having affinity for serum albumin are useful for tumor targeting. Conjugate molecules comprising a serum albumin binding peptide fused to a biologically active molecule demonstrate modified pharmacokinetic properties as compared with the biologically active molecule alone, including tissue (e.g., tumor) uptake, infiltration, and diffusion.... Agent: Genentech, Inc.

20070202047 - Polyamine-substituted ligands for use as contrast agents: and optionally at least one of the carboxylic groups of the chelating molecule is further reacted with a monoalkylamine having 1 to 18 carbon atoms to form an amide bond; provided that at least one of R1, R2 is other than H. Furthermore, the invention relates to contrast agents for... Agent: Connolly Bove Lodge & Hutz LLP

20070202046 - Implantable device formed from polymer blends: A biocompatible material may be configured into any number of implantable medical devices including intraluminal stents. Polymeric materials may be utilized to fabricate any of these devices, including stents. The stents may be balloon expandable or self-expanding. The polymeric materials may include additives such as drugs or other bioactive agents... Agent: Philip S. Johnson Johnson & Johnson

20070202048 - Methods, systems, and reagents for delivery to bone of an osteoinductive factor with a contrast agent: The present invention is directed to methods, systems and reagents for providing contrast media that are compatible with osteoinductive factor induced bone formation.... Agent: Fox Rothschild, LLP

20070202049 - Oral dosage form comprising an antimisuse system: An oral solid dosage form containing one or several active principle(s) having analgesic properties, the composition of said dosage form being such that it prevents the misuse of said dosage form through the liquid extraction of the active principle(s) contained therein, using commonly available solvents. Said oral solid dosage form... Agent: Patton Boggs LLP

20070202051 - Aerosols for sinunasal drug delivery: A pharmaceutical aerosol is disclosed which is suitable for delivering an active compound to the mucosa of the nasal cavity or of the paranasal sinuses. The aerosol is characterised in that its pressure is not constant, but pulsates at a frequency of about 10 to 90 Hz. The mass median... Agent: Edwards Angell Palmer & Dodge LLP

20070202050 - Pharmaceutical formulations: An aspect of the present invention provides for a medicament including a solution containing pleconaril or a pharmaceutically acceptable salt thereof, wherein at least one solvent comprising said solution is a pleconaril-dissolving glyceride oil, and the solution is suitable for inhalation administration as an aerosol mist.... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20070202054 - Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid: An inhalable formulation containing SAE-CD and corticosteroid is provided. The formulation is adapted for administration to a subject by nebulization with any known nebulizer. The formulation can be included in a kit. The formulation is administered as an aqueous solution, however, it can be stored as a dry powder, ready-to-use... Agent: Innovar, LLC

20070202055 - Pharmaceutical formulations: An aspect of the present invention provides for a medicament suitable for administration as a nasal inhalant including an aqueous carrier and suspended therein particulate pleconaril, the aqueous carrier including a thixotropic composition including microcrystalline cellulose and a polymer selected from an alkali metal carboxyalkylcellulose, a polyvinylpyrrolidone polymer, and mixtures... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20070202053 - Pharmaceutical formulations for dry powder inhalers comprising a low-dosage strength active ingredient: The invention provides a formulation to be administered as dry powder for inhalation suitable for efficacious delivery of low-dosage strength active ingredients to the low respiratory tract of patient. In particular, the invention provides a formulation comprising microparticles constituted of microparticles of a low-dosage strength active ingredient and microparticles of... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070202057 - Disintegrable oral films: A water soluble film that is disintegrable in the oral cavity to deliver an active agent is provided. The disintegrable film includes at least one water soluble polymer and an active agent. Also provided are methods for preparing the disintegrable oral film and for using the disintegrable film to administer... Agent: Novartis Corporate Intellectual Property

20070202056 - Oral composition for improving mouth environment: A solid oral composition for providing a mouthwash efficacious effect comprising a hygroscopic base, carbamide peroxide, and a bacterial immobilizing agent.... Agent: James Sonntag James Sonntag, Patent Attorney

20070202059 - Stable one-part aqueous tooth whitening composition: The invention relates to a high-temperature stable, one-part, aqueous tooth bleaching composition for contacting a tooth surface. The composition comprises a bleaching agent comprising a high level of a aqueous hydrogen peroxide. The bleaching agent is derived from multiple components within the composition and comprises at least about 15% by... Agent: Rudoler & Derosa LLC Attn: Docket Clerk

20070202061 - Cosmetic skincare applications employing mineral-derived tubules for controlled release: Compositions and methods pertaining to the topical treatment of skin are disclosed. The present invention relates to topical compositions for regulating the condition of skin, especially for regulating visible and/or tactile discontinuities in skin associated with skin aging, environmental affects and the like. One embodiment of the present invention relates... Agent: Basch & Nickerson LLP

20070202060 - Retinoid-containing preparations: Preparations comprising a. at least one retinoid, b. at least one water-soluble antioxidant, c. at least one oil-soluble antioxidant and d. 0.01 to 10% by weight of at least one UV filter, wherein, in the preparations, per part by weight of retinoid, at least 1 part by weight of one... Agent: Connolly Bove Lodge & Hutz, LLP

20070202062 - Natural deodorant compositions comprising renewably-based, biodegradable 1,3-propanediol: Disclosed herein are all natural or substantially natural deodorant and antiperspirant compositions comprising 1,3-propanediol wherein the 1,3-propanediol in said all natural or substantially natural deodorant or antiperspirant composition has a bio-based carbon content of about 1% to 100%. In addition, it is preferred that the 1,3-propanediol be biologically-derived, and wherein... Agent: Mccarter & English, LLP Basil S. Krikelis

20070202063 - Benefit agent containing delivery particle: The present invention relates to benefit agent containing delivery particles, compositions comprising said particles, and processes for making and using the aforementioned particles and compositions. When employed in compositions, for example, cleaning or fabric care compositions, such particles increase the efficiency of benefit agent delivery, there by allowing reduced amounts... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20070202064 - Rheology modifier/hair styling resin: A rheology modifier/hair styling resin which is a crosslinked, linear poly(vinyl amide/polymerizable carboxylic acid) copolymer exhibits advantageous hair care properties of high viscosity and long-lasting curl retention.... Agent: International Specialty Products William J. Davis, Esq.

20070202067 - Stable oil-in-water and water/oil/water multiple emulsions and hair treating compositions comprising them: The present invention provides an oil-in-water or water/oil/water multiple emulsion, or a mixture thereof, comprising (A) a organopolysiloxane elastomer crosslinked with polyether chains and (B) at least one thickener selected from the group of a polyacrylamide homo- or copolymer, a cellulose ether, a non-silicone cationic polymer or a thickening system... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20070202068 - Hair styling cream: The present invention relates to hair styling creams comprising a crosslinked silicone polymer; an alkoxylated compound selected from polyethylenoxides and polyalkoxylated silicone compounds; emulsifier; a fatty phase; and an aqueous phase. The cream can be transferred into rope-, thread-, or fiber-like structures when distributed in the hands. It gives a... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20070202070 - Moisture retention polymer compound: The present invention relates to (1) a moisture retention polymer compound comprising a structural unit including a multi-branched polysaccharide derivative in which the hydroxyl group (OH) may be substituted by OR wherein R represents a hydrogen atom, a hydrocarbon having 1 to 30 carbon atoms, or a hydrocarbon having 1... Agent: Sughrue Mion, PLLC

20070202071 - Emulsions comprising a dendritic polymer and use of a dendritic polymer as an emulsification agent: The invention relates to novel emulsions comprising a dendritic polymer. The invention also relates to the use of a dendritic polymer as an emulsification agent. The inventive emulsions are suitable for use in the cosmetics, detergents, paint and coatings industries.... Agent: Jean Louis Seugnet Rhodia Inc

20070202065 - Process for permanently reshaping the hair using particular aminosilicones: A process for permanently reshaping keratin fibres, comprising the application to the keratin fibres, before reducing and/or after the fixing, of a pre-treatment and/or post-treatment cosmetic composition comprising, in a cosmetically acceptable medium, at least one aminosilicone, as defined herein, in non-microemulsified form.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070202072 - Ethoxylated polyurethane viscosity enhancers: The invention provides personal care products comprising fatty ethoxylated dimeric urethane compounds that enhance the viscosity of constituent water based surfactant systems. In compositions and methods of the invention, ethoxylated nonionic, urethane dimers increase the viscosity of water based surfactant systems and serve as thickeners. These thickeners produce clear solutions... Agent: Coleman Sudol Sapone, P.C.

20070202073 - Personal care and cosmetics compositions comprising biologically-based mono and di esters: Personal care compositions comprising esters of 1,3-propanediol and acceptable carriers are provided. The esters can have at least 3% biobased carbon, and the compositions can further comprise 1,3-propanediol that is biologically-derived. Also provided are processes for producing personal care compositions comprising esters of 1,3-propanediol and acceptable carriers. The processes comprise... Agent: Mccarter & English, LLP Basil S. Krikelis

20070202066 - Cosmetic preparation for eyelash: The present invention relates to a cosmetic for eyelash comprising a film-forming polymer (a) having a rate of change in polymer content (ΔW) of 13% or more, and water, wherein a content of the film-forming polymer (a) is 0.6 to 50% by mass. The cosmetic for eyelash according to the... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070202074 - Polymeric precursors of non-absorbable, in situ-forming hydrogels and applications thereof: The present invention is directed toward an injectable, single- or multiple-component polymeric liquid precursor of an in situ-forming, non-absorbable, flexible, and resilient hydrogel or semi-solid that can be used in non-surgical, minimally invasive treatment of herniated disc.... Agent: Leigh P. Gregory Attorney At Law

20070202075 - Tissue adhesives and sealants and method for their use: Compositions provided by mixing a biotin-containing component and an avidin-containing component are useful as an adhesive or sealant for medical/surgical uses.... Agent: United States Surgical, A Division Of Tyco Healthcare Group Lp

20070202076 - Methods and compositions for the targeted delivery of therapeutics: Disclosed herein are compositions and methods for the targeted delivery of a therapeutic agent. In one aspect, the invention pertains to glycopolymer-based particles complexed with a nucleic acid-based therapeutic. Other aspects of the invention relate to methods for treating various conditions by administering the particle compositions of the invention. In... Agent: Olson & Hierl, Ltd.

20070202077 - Use of high-dose oxazaphosphorine drugs for treating immune disorders: This disclosure relates, at least in part, to methods of eliminating adverse immune reactions in a subject in need thereof including those associated with autoimmune diseases, allergic reactions and transplant rejection, including administration of a lymphocytotoxic non-myeloablative amount of a oxazaphosphorine drug to the subject.... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20070202078 - Method of treating viral infections: A method of pharmaceutical therapy includes co-administering: (A) interferon or derivative thereof with a low dose of B ribavirin ≦400 mg/day or ≦6 mg/kg/day), or related compound, where (B) provides a clinically effective blood level in portal circulation but less than clinically effective blood level in peripheral circulation, thereby providing... Agent: Caesar, Rivise, Bernstein, Cohen & Pokotilow, Ltd.

20070202079 - Therapeutic compositions and methods useful in modulating protein tyrosine phosphatases: The invention relates to therapeutic compositions useful in treating prostate cancer. In one embodiment, a therapeutic composition containing a pentavalent antimonial is provided. The pentavalent antimonial is preferably sodium stibogluconate and biological equivalents thereof. The therapeutic composition comprises an effective amount of pentavalent antimonial that can be used in treating... Agent: Morgan Lewis & Bockius LLP

20070202080 - Gene delivery system containing relaxin gene and pharmaceutical composition using relaxin: The present invention relates to a novel gene delivery system and recombinant adenovirus comprising the relaxin-encoding sequence to enhance transduction efficiency of transgenes, a pharmaceutical anti-tumor composition comprising the recombinant adenovirus, a pharmaceutical composition having improved tissue penetration potency and a pharmaceutical composition for treating a disease or disorder associated... Agent: The Rafferty Patent Law Firm

20070202081 - Prevention and treatment of vascular disease with recombinant adeno-associated virus vectors encoding apolipoprotein a-i and apolipoprotein a-i milano: Described herein is a gene therapeutic approach to the prevention and treatment of vascular disease and coronary heart disease; in particular, atherosclerosis. The inventive methods may be used in the prevention and treatment of atherosclerosis, as well as any disease or physiological condition in which atherosclerosis plays a role. The... Agent: Davis Wright Tremaine LLP

20070202082 - Promoters for rna interference: This invention provides vector systems based on the promoters of Epstein-Barr virus-encoded small RNAs that can be used to express and deliver desired RNA molecules such as small hairpin RNAs in mammalian cells. Such small hairpin RNAs are useful for RNA interference.... Agent: Cooper & Dunham, LLP

20070202087 - Composition: The present invention provides the use of the probiotic micro organism deposited under the accession number NCIMB 41117, in the manufacture of a composition for the treatment of non specific dietary sensitivity in a dog or a cat. The present invention also provides a method for the treatment of non... Agent: Fulbright & Jaworski, LLP

20070202088 - Microorganisms and methods for treating poultry: An isolated Bacillus strain LSSAO1 is provided. When fed to a bird, this and other Bacillus strains described herein provide benefits to the birds. For example, administration of the one or more Bacillus strain can increase low G+C, gram positive bacteria in the gastrointestinal flora of the bird. These type... Agent: Whyte Hirschboeck Dudek S.c.

20070202089 - Novel bacillus thuringiensis crystal polypeptides, polynucleotides, and compositions thereof: The present invention provides insecticidal polypeptides related to Bacillus Cry2 polypeptides. Nucleic acids encoding the polypeptides of the invention are also provided. Methods for using the polypeptides and nucleic acids of the invention to enhance resistance of plants to insect predation are encompassed.... Agent: Pioneer Hi-bred International, Inc.

20070202084 - Bioabsorbable implant of hyaluronic acid derivative for treatment of osteochondral and chondral defects: A method for treating an osteochondral defect or a chondral defect in a subject includes implanting a composite in a site of the osteochondral or chondral defect. The composite includes a hyaluronic acid derivative; and at least one member of the group consisting of a cell, a cellular growth factor... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20070202083 - Carbon monoxide improves outcomes in tissue and organ transplants and suppresses apoptosis: The present invention features methods for transplanting organs, tissues and individual cells. Also featured are methods for maintaining cells in vitro and for enhancing survival and/or function of cells following transplantation. The methods include the administration of carbon monoxide in an amount sufficient to enhance cell survival and/or function.... Agent: Fish & Richardson PC

20070202085 - Systems and methods for monitoring immune responses and predicting outcomes in transplant recipients: The present invention is related to transplant rejection. In particular, the present invention relates to determining the functional status of alloreactive T cells and correlating the functional status to in vivo immune responses (e.g., tolerance, rejection, or absence of rejection mediated by T cells). The present invention finds use in... Agent: Medlen & Carroll, LLP

20070202086 - Vascular stem cells and uses thereof: The present invention relates to a method for obtaining a cell population enriched in vascular stem cells. Vascular stem cells can be used for a variety of purposes, especially in cell therapy for the treatment of ischemic diseases, including peripheral ischemia and myocardial infarction.... Agent: Young & Thompson

20070202090 - Water soluble form of coenzyme q10 in the form of an inclusion complex with beta-cyclodextrin, process of preparing, and use thereof: An inclusion complex comprising coenzyme Q10 and β-cyclodextrin, its manner of preparation, and its use in products, such as, for example, pharmaceuticals, cosmetics, and aliments is disclosed. β-cyclodextrin is dissolved in water at a temperature elevated above room temperature, such as, for example, between 55° C. and water's boiling temperature.... Agent: Smith Moore LLP

20070202092 - Use of beta-1,3 (4)-endoglucanohydrolase beta-1,3 (4) glucan, diatomaceous earth, mineral clay and glucomannan to augment immune function: A method for the augmentation of immune function is described. The invention comprises a combination of β-1,3(4)-endoglucanohydrolase, β-1,3(4)glucan, diatomaceous earth, mineral clay and glucomannan, which is fed to or consumed by mammalian or avian species in amounts sufficient to augment immune function. The invention described may be admixed with feeds... Agent: Cook, Alex, Mcfarron, Manzo, Cummings & Mehler Ltd

20070202093 - Systems and methods to reduce gel retraction: Methods for ameliorating stent graft migration and endoleak using treatment site-specific cell growth promoting compositions in combination with stent grafts are disclosed. Also disclosed are application of cell growth promoting compositions such as, but not limited to, autologous platelet gel compositions directly to treatment sites during or after stent graft... Agent: Medtronic Vascular, Inc.IPLegal Department

20070202094 - Timp3 as vegf inhibitor: Polypeptides or proteins comprising tissue inhibitor of mettaloproteinases-3 (TIMP3) or variants of TIMP3 can be used to substantially inhibit vascular endothelial growth factor (VEGF) binding to VEGF receptor-2 (VEGFR2/KDR/Flk-1)) without substantially inhibiting VEGF binding to VEGF receptor 1 (VEGFR1/Flt-1).... Agent: Tarolli, Sundheim, Covell & Tummino L.L.P.

20070202095 - Chlorine dioxide based cleaner/sanitizer: This invention relates to an improved chlorine dioxide solution or liquid mixture containing a phosphate and, as well, as to a composition for forming the chlorine dioxide and phosphate liquid mixture. This improved chlorine dioxide solution is used to clean and/or sanitize without causing corrosion. The corrosion nature of the... Agent: Gus Hampilos Patent Counsel

20070202096 - Xaf genes and polypeptides: methods and reagents for modulating apoptosis: The invention provides novel XAF nucleic acid sequences. Also provided are XAF polypeptides, anti-XAF antibodies, and methods for modulating apoptosis and detecting compounds which modulate apoptosis.... Agent: Philip Swain, Phd C/o Gowling Lafleur Henderson

20070202098 - Her2/neu optimized fc variants and methods for their generation: The present invention relates to Her2/neu optimized Sc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants.... Agent: Morgan, Lewis & Bockius, LLP

20070202097 - Monoclonal antibodies that recognise mucosal addressin cell adhesion molecule-1 (madcam-1), soluble madcam-1 and uses thereof: The present application describes novel monoclonal antibodies, fragments and derivatives thereof which recognise mucosal addressin cell adhesion molecule-1 (MAdCAM-1). Also described are methods which utilise the monoclonal antibodies. Further, a soluble form of MAdCAM-1 is described as well as methods which utilise its presence in a subject.... Agent: Edwards Angell Palmer & Dodge LLP

20070202099 - Antibody drug: The present invention provides an agent for improving the blood stability of an endogenous ligand, which comprises an antibody that has affinity to the mammalian endogenous ligand but substantially does not neutralize the same, and the above-described agent for the prophylaxis and/or treatment for a disease for which an increase... Agent: Edwards Angell Palmer & Dodge LLP

20070202101 - Combination therapy using anti-egfr antibodies and anti-hormonal agents: The invention relates to a combination therapy for the treatment of tumors and tumor metastases, preferably breast and prostate tumors, comprising administration of anti-EGFR (Her1) antibodies and anti-hormonal agents, optionally together with cytotoxic/chemotherapeutic agent. The method and the pharmaceutical compositions comprising said agents can result in a synergistic potentiation of... Agent: Kirkpatrick & Lockhart Preston Gates Ellis LLP (formerly Kirkpatrick & Lockhart Nicholson Graham)

20070202100 - Pd-1, a receptor for b7-4, and uses therefor: The invention identifies PD-1 as a receptor for B7-4. B7-4 can inhibit immune cell activation upon binding to an inhibitory receptor on an immune cell. Accordingly, the invention provides agents for modulating PD-1, B7-4, and the interaction between B7-4 and PD-1 in order to modulate a costimulatory or an inhibitory... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20070202106 - Compositions and methods for the treatment of cancer: The present invention includes compositions and methods for the treatment, diagnosis and prognosis of cancers by detecting the level of IL-13 expression in cancerous cells in the tissue microenvironment as an indicator of controlling the type of immune response mounted against the cancer.... Agent: Chalker Flores, LLP

20070202103 - Compounds for targeting: The invention provides a compound comprising a target specific portion and an effector portion wherein the target specific portion comprises or consists of a monoclonal antibody having specificity for oncofoetal fibronectin, or a fragment or variant thereof which retains the antigen binding specificity of the parent monoclonal antibody and the... Agent: Patrea L. Pabst Pabst Patent Group LLP

20070202105 - Domain antibody construct: (c) a human or primate heavy chain constant region sequence having a truncated CH1 domain of not more than 20 residues, wherein said modified hinge region sequence contains either a deletion or a single amino acid substitution of at least one cysteine residue which normally facilitates disulfide bond formation between... Agent: Morrison & Foerster LLP

20070202102 - High-yield method for the production of human antibodies blocking the biological activity of a human cytokine: The invention concerns a pharmaceutical composition comprising, as the active ingredient, human natural antibodies of the IgG isotype, that neutralize the activity of a human cytokine selected from VEGF, IFNα, IL-4, TNFα and TGFβ, the said neutralizing antibodies inhibiting at least 50% of the maximum biological activity induced by an... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20070202104 - Treatment of spondyloarthropathies using tnfalpha inhibitors: Methods for treating spondyloarthropathies, including ankylosing spondylitis, using TNFα inhibitors are described.... Agent: John D. Conway, Esq. Abbott Bioresearch Center, Inc.

20070202108 - Glycoprotein vi antibodies and methods thereof: The present invention describes antibodies generated against platelet membrane glycoprotein VI-(GPVI), methods of producing the anti-GPVI antibodies, and the use of these antibodies as research and immunotherapeutic agents, in particular, as antithrombotic therapeutic agents.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070202107 - Novel kinases: The present invention relates to kinase polypeptides, nucleotide sequences encoding the kinase polypeptides, as well as various products and methods useful for the diagnosis and treatment of various kinase-related diseases and conditions. Through the use of a bioinformatics strategy, mammalian members of the of PTK's and STK's have been identified... Agent: Foley And Lardner LLP Suite 500

20070202110 - Angiogenesis inhibiting molecules and their use in the treatment and diagnosis of cancer: The present invention relates to angiogenesis inhibiting molecules that are the monoclonal antibody H33 or fragments or derivatives thereof, to their use in the treatment of cancer, in particular the treatment of solid tumors and to therapeutic and diagnostic compositions comprising them. The invention relates in particular to humanized derivatives... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20070202112 - Compositions and methods for detecting cancer and for inhibiting metastatis: The present invention relates to compositions and methods for detecting cancer (e.g., prostate cancer) and for inhibiting metastasis (e.g., associated with prostate cancer). In particular, the present invention provides methods of detecting vimentin expression and secretion and for characterizing cancer (e.g., prostate cancer). In addition, the present invention provides methods... Agent: Medlen & Carroll, LLP

20070202113 - Cytotoxicity mediation of cells evidencing surface expression of trop-2: The present invention relates to a method for producing cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be... Agent: Mchale & Slavin, P.A.

20070202109 - Method of diagnosing breast cancer: Compositions and objective methods for detecting, diagnosing, and treating breast cancer (BRC) are described herein. In particular, the present invention describes three BRC-associated genes, referred to herein as A5657, B9769, and C7965, up-regulated in BRC cells as compared to normal cells. In one embodiment, the diagnostic method involves determining the... Agent: Townsend And Townsend And Crew, LLP

20070202114 - P38 mapk pathway predicts endocrine-resistant growth of human breast cancer and provides a novel diagnostic and treatment target: Acquired and de novo endocrine resistance are major clinical problems in the management of breast cancer patients. Though the antiestrogen tamoxifen prolongs disease-free and overall survival in the adjuvant setting, and induces remissions in over half of the patients with estrogen receptor positive metastatic disease, all patients eventually acquire tamoxifen... Agent: Fulbright & Jaworski, LLP

20070202111 - Use of antibodies to the gamma 2 chain of laminin 5 to inhibit tumor growth and metastasis: The present invention provides a methods and compositions for inhibiting tumor growth and/or metastasis involving the administering to a subject with a laminin 5-secreting tumor of an amount effective to inhibit tumor growth and/or metastasis of an antibody that binds to one or more epitopes of the laminin 5 γ2... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20070202115 - Preparation for the prevention and/or treatment of a tissue change of mesenchymal origin: The present invention concerns a preparation for preventing and/or treating a tissue change, wherein the tissue change involves tissue of mesenchymal origin or tissue changes derived therefrom and the preparation contains an antiviral agent.... Agent: Wood, Phillips, Katz, Clark & Mortimer

20070202116 - Treatment of micro-organism infection: The present invention is concerned with novel antibodies, medicaments, pharmaceutical packs, methods of manufacture of medicaments and methods for the treatment of micro-organism infections, particularly for the treatment of Staphylococcal infections such as S. aureus infections including MRSA infections.... Agent: Fish & Richardson PC

20070202117 - Compositions and methods of modulating the immune response: The present invention provides methods and compositions of enhancing the immune response to an antigen.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.C.

20070202118 - Novel peroxiredoxin defense system from mycobacterium tuberculosis: The present invention relates to methods of preventing and treating tuberculosis in a subject infected with Mycobacterium tuberculosis. The method involves inhibiting AhpD in the subject under conditions effective to make the pathogen susceptible to antimicrobial reactive nitrogen intermediates or reactive oxygen intermediates. The present invention also relates to methods... Agent: Nixon Peabody LLP - Patent Group

20070202119 - Method of therapy: Numerous diseases have been linked to the production of regulator cells. The present invention relates to the observation that the immune system is cycling in these diseases. Based on these observations, the present invention provides methods for treating diseases such as cancer and a HIV infection. The present invention also... Agent: Faegre & Benson LLP Patent Docketing

20070202121 - Spas-1 cancer antigen: Compounds and methods for inducing protective immunity against cancer are disclosed. The compounds provided include polypeptides that contain at least one immunogenic portion of one or more SPAS-1 proteins and DNA molecules encoding such polypeptides. Such compounds may be formulated into vaccines and pharmaceutical compositions for immunization against cancer, or... Agent: Bozicevic, Field & Francis LLP

20070202120 - Yellow fever mosquito deoxyribonucleoside kinases and its use: This invention relates to mosquito multisubstrate deoxyribonucleoside kinases and their use in gene therapy. More specifically the invention provides novel deoxyribonucleoside kinases derived from Aedes aegypti. In further aspects the invention provides novel polynucleotides encoding the mosquito deoxyribonucleoside kinases, vector constructs comprising the polynucleotide, host cells carrying the polynucleotide or... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20070202122 - Non-splicing variants of gp350/220: Compositions comprising gp350 variant DNA and amino acid sequences are provided, as are vectors and host cells containing such sequences. Also provided is a process for producing homogeneous gp350 protein recombinantly and in the absence of production of gp220 protein, pharmaceutical compositions containing such protein and prophylactic treatments making use... Agent: Johnathan Klein-evans

20070202123 - Fusion proteins comprising dp-178 and other viral fusion inhibitor peptides useful for treating aids: The present invention relates to fusion peptides which exhibit potent anti-retroviral activity. The fusion peptides of the invention comprise a macromolecular carrier group fused to a gp41-derived DP178 (SEQ ID NO:1) peptide corresponding to amino acids 638 to 673 of the HIV-1LA1 gp41 protein, or fragments, analogs or homologs of... Agent: Jones Day

20070202124 - Method for the production of purified invasin protein and use thereof: A method for production of highly purified invasin proteins is disclosed. Also disclosed are vaccine and adjuvant compositions comprising highly purified invasin proteins and the use of highly purified adjuvant proteins to induce an immune response and for administration of drugs.... Agent: Senniger Powers

20070202125 - Inhibiting rejection of a graft: Disclosed are methods for inhibit rejection of a graft in a patient. The methods involve treating the graft with a molecule which binds to a co-stimulatory protein of antigen-presenting cells. Useful molecules include chimeras having enzymatically inactive polypeptides bonded to polypeptides which bind to co-stimulatory proteins of antigen-presenting cells. Also... Agent: Fish & Richardson PC

20070202126 - Bio-derived 1,3-propanediol and its conjugate esters as natural and non irritating solvents for biomass-derived extracts, fragrance concentrates, and oils: Compositions comprising 1,3-propanediol and an extraction product are provided, and the 1,3-propanediol in the composition is biologically derived. Also provided are processes for extracting an extract from a source. These processes comprise providing an ester of 1,3-propanediol and mixing the 1,3-propanediol ester with the source. This serves to extract the... Agent: Mccarter & English, LLP Basil S. Krikelis

20070202127 - Nucleic acids encoding dp-178 and other viral fusion inhibitor peptides useful for treating aids: The present invention relates to peptides which exhibit potent anti-retroviral activity. The peptides of the invention comprise DP178 (SEQ ID:1) peptide corresponding to amino acids 638 to 673 of the HIV-1LAI gp41 protein, and fragments, analogs and homologs of DP178. The invention further relates to the uses of such peptides... Agent: Jones Day

20070202128 - Immunomodulatory oligonucleotides: Oligonucleotides containing unthylated CpG dinucleotides and therapeutic utilities based on their ability to stimulate an immune response in a subject are disclosed. Also disclosed are therapies for treating diseases associated with immune system activation that are initiated by unthylated CpG dinucleotides in a subject comprising administering to the subject oligonucleotides... Agent: Wolf Greenfield & Sacks, P.C.

20070202129 - Use of the neurotoxic component of a botulinum toxin for the treatment of pain associated with muscle activity or contracture: A method and composition for treating a patient suffering from a disease, disorder or condition and associated pain include the administration to the patient of a therapeutically effective amount of a neurotoxin selected from a group consisting of Botulinum toxin types A, B, C, D, E, F and G.... Agent: Allergan, Inc.

20070202130 - Anthrax antigens and methods of use: Anthrax antigens are provided that find use as immunogens and vaccines.... Agent: Cooley Godward Kronish LLP Attn: Patent Group

20070202131 - Use of mycrobacterial vaccines in cd4+ or cd8+ lymphocyte-deficient mammals: Methods of treating a mammal that is deficient in CD4+ and/or CD8+ lymphocytes are provided. The methods comprise inoculating the mammal with an attenuated mycobacterium in the M. tuberculosis complex. In these methods, the mycobacterium comprises two deletions, wherein a virulent mycobacterium in the M. tuberculosis complex having either deletion... Agent: Amster, Rothstein & Ebenstein LLP

20070202132 - Allergenic proteins and peptides from dog dander and uses therefor: Isolated nucleic acids encoding allergens of Canis familiaris, Can f I or Can f II, are disclosed. A cDNA encoding a peptide having a Can f I activity and a predicted molecular weight of about 19,200 daltons is also described. A cDNA encoding a peptide having Can f II activity... Agent: Lahive & Cockfield, LLP

20070202133 - Benzimidazole compounds for modulating ige and inhibiting cellular proliferation: The present invention is directed to small molecule inhibitors of the IgE response to allergens, which are useful in the treatment of allergy and/or asthma or any diseases where IgE is pathogenic. This invention also relates to benzimidazole molecules that are cellular proliferation inhibitors and thus are useful as anticancer... Agent: Knobbe Martens Olson & Bear LLP

20070202134 - Muc1 antagonist enhancement of death receptor ligand-induced apoptosis: The present invention relates to methods of enhancing death receptor-induced apoptosis in MUC1 expressing cells comprising contacting the MUC1 expressing cells with an effective amount of a MUC1 antagonist.... Agent: Fulbright & Jaworski L.L.P.

20070202135 - Ionized compositions and methods of use therefore: This invention relates to methods for preparing an ionic composition suitable for use as a cosmetic product, products containing such compositions, and containers for containing and dispensing such products.... Agent: Buchanan, Ingersoll & Rooney LLP

20070202138 - Antimicrobial compositions and method: Compositions for antimicrobial, antibacterial, antiviral, fungicidal and sporicidal applications comprise a mixture of alkyl betaine and alkyl amine oxide components together with a protonating agent. The compositions are particularly effective in the treatment and elimination of microorganisms in planktonic cell form as well as in sessile cell form in biofilms.... Agent: Pearne & Gordon LLP

20070202137 - Device for sensing of motile living organisms and uses thereof: The present invention relates to the field of devices for studying behaviour of motile living organisms in a multiplexed array format. The present invention provides devices comprising a solid porous support having first and second surfaces, said first surface comprising an agent and/or condition delineating behavioural and/or physical barriers for... Agent: Amster, Rothstein & Ebenstein LLP

20070202136 - Method for reducing the contamination properties of a surface by micro-organisms: A method for reducing the contamination properties by micro-organisms of a surface made of a mineral material, the surface having an area of at least 0.1 m2, the method including the following steps: a) application, onto the surface to be treated, of a layer of a solution or of an... Agent: Young & Thompson

20070202139 - Use of microcapsules for making paints and lacquers: The invention provides microcapsules having an average diameter of 0.1 to 25 μm, obtained by a process (a) or (b), wherein, (a1) preparing an aqueous emulsion comprising actives and optionally oil components and/or emulsifiers; (a2) treating the emulsifier with an aqueous solution of anionic polymers to form a matrix; (a3)... Agent: Cognis Corporation Patent Department

20070202140 - Thrombin receptor antagonists as prophylaxis to complications from cardiopulmonary surgery: Disclosed herein are methods of preventing, inhibiting, or ameliorating complications associated with cardiopulmonary bypass surgery by the use of a thrombin receptor antagonist compound. Among the thrombin receptor antagonist compounds useful in these methods are those of Formulas I and II, described herein. Examples of such thrombin receptor antagonists include:... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20070202141 - Synthetic aggregation pheromone for manipulating the behaviour of codling moth, cydia pomonella, larvae: This invention relates to a composition and procedure for manipulating the behaviour of codling moth larvae, Cydia pomonella (L.) (Lepidoptera: Olethreutidae). In particular, this invention relates to the use of specific pheromone components for manipulating the behaviour of C. pomonella larvae. A composition of chemicals for manipulating the behaviour of... Agent: Oyen, Wiggs, Green & Mutala LLP 480 - The Station

20070202142 - Biomaterial, injectable implant comprising it, its method of preparation and its uses: This invention relates to a biomaterial comprising an injectable bioresorbable polysaccharide composition wherein the polysaccharide may be succinochitosan glutamate. This invention also relates to a biomaterial comprising an injectable bioresorbable polysaccharide composition in which resorbable particles may be in suspension, the said particles comprising or consisting essentially of chitin and/or... Agent: Greenberg Traurig, LLP

20070202143 - Direct application of non-toxic crosslinking reagents to restabilize surgically destabilized intervertebral joints: A method of improving the resistance of collagenous tissue subject to elevated collagenous tissue stress as a result of tissue removing surgical decompression surgery, comprising contacting at least a portion of the remaining collagenous tissue with an effective amount of a crosslinking reagent.... Agent: Robert Berliner Berliner & Associates

20070202146 - Implantable device formed from polymer and plasticizer blends having modified molecular structures: A biocompatible material may be configured into any number of implantable medical devices including intraluminal stents. Polymeric materials may be utilized to fabricate any of these devices, including stents. The stents may be balloon expandable or self-expanding. The polymeric materials may include additives such as drugs or other bioactive agents... Agent: Philip S. Johnson Johnson & Johnson

20070202144 - Coated implants, their manufcturing and use thereof: The present invention relates to a method of coating of a device, preferably implants, with a substance comprising the steps of (a) contacting said device into a solution of said substrate or substance, and (b) drying said device while being submerged in said solution. The present invention also relates to... Agent: Faegre & Benson LLP Patent Docketing

20070202148 - High density fibrous polymers suitable for implant: This invention includes malleable, biodegradable, fibrous compositions for application to a tissue site in order to promote or facilitate new tissue growth. One aspect of this invention is a fibrous component that provides unique mechanical and physical properties. The invention may be created by providing a vessel containing a slurry,... Agent: Kensey Nash Corporation

20070202145 - Method for incorporation of bioactives into a porous hydrophobic polymer scaffold: This idea represents a method for incorporation of a therapeutic molecule, preferably a protein or a growth factor, into a biodegradable scaffold, specifically one that is made of a foam nonwoven composite. The process utilizes a solvent preferably tertiary butanol to facilitate the infiltration of the particles of the therapeutic... Agent: Philip S. Johnson Johnson & Johnson

20070202147 - Poly(ester amide)-based drug delivery systems with controlled release rate and morphology: A method of forming a coating on a medical device having a controlled morphology is described.... Agent: Squire, Sanders & Dempsey LLP

20070202149 - Hydrophobic cross-linked gels for bioabsorbable drug carrier coatings: Coatings for medical devices, methods of making the coatings, and methods of using them are described.... Agent: Lahive & Cockfield, LLP

20070202150 - Implantable device formed from polymer and plasticizer blends: A biocompatible material may be configured into any number of implantable medical devices including intraluminal stents. Polymeric materials may be utilized to fabricate any of these devices, including stents. The stents may be balloon expandable or self-expanding. The polymeric materials may include additives such as drugs or other bioactive agents... Agent: Philip S. Johnson Johnson & Johnson

20070202151 - Intravesical drug delivery device and method: Implant devices for intravesical administration and local drug delivery. The device has a body which includes a hollow tube formed of a biocompatible material; at least one reservoir in the tube which contains a drug; and one or more apertures through which the drug can be released. The device is... Agent: Sutherland Asbill & Brennan LLP

20070202152 - Method for encapsulation of orally ingested materials to alter the site of digestion, site of action, or stability: Comestible materials encapsulated by a film-forming composition including a plant protein source and methods of forming the same are provided. The film-forming composition affects the site of digestion of the comestible material within the digestive tract of an animal or a human thereby allowing the material to be most effectively... Agent: Hovey Williams LLP

20070202153 - Liquid concentrated formula: The invention pertains to a liquid complete nutritional composition suitable for feeding cachectic patients, having an energy density of at least 1.45 kcal/ml. The composition comprises a protein fraction in an amount of 7.8-12 g per 100 ml, a carbohydrate fraction, and a lipid fraction. At least 70 wt. %... Agent: Foley And Lardner LLP Suite 500

20070202154 - Process for promoting overall health of an animal: The process of the present invention comprises an animal food composition that is fed to animals and is pro-nutritional, and is convenient to the pet owner. When the pet owner feeds the animal food composition to the animal, the ingested composition promotes a healthy body weight in the animal and... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20070202156 - Adhesive preparation comprising sufentanil and methods of using same: The present invention provides percutaneously absorbable adhesive preparations and transdermal compositions comprising Sufentanil, which are obtained from economic starting materials, have a constitution simpler than that of conventional Sufentanil adhesive preparations, and have effective skin permeability. The preparations and compositions comprise two polyisobutylenes having different molecular weights, a tackifier, a... Agent: Foley And Lardner LLP Suite 500

20070202155 - Low dose no donor-containing transdermal patch: The present invention is drawn to a transdermal patch for the delivery of a nitroglycerin or other NO donor. The patch can comprise a backing layer, and a nitroglycerin-containing composition or other NO donor-containing composition which is supported at least in part by the backing layer. The transdermal patch can... Agent: Thorpe North & Western, LLP.

20070202157 - Liposomal phosphodiester, phosphorothioate, and p-ethoxy oligonucleotides: An improved delivery system for antisense oligonucleotides involves a liposomal composition, comprising a liposome which consists essentially of neutral phospholipids and an antisense oligonucleotide that is entrapped in the liposome and is selected from the group consisting of phosphodiester oligonucleotides, phosphorothioate oligonucleotides, and p-ethoxy oligonucleotides.... Agent: Fulbright & Jaworski L.L.P.

20070202158 - Methods of administering water-soluble prodrugs of propofol for extended sedation: A method of administering a prodrug of propofol, preferably O-phosphonooxymethyl propofol disodium salt, comprises the oral, intragastric, or intraintestinal administration of the prodrug in amounts sufficient to induce or maintain a generalized anesthetized state, a conscious sedated state, or to treat insomnia, anxiety, nausea, vomiting, pruritus, epilepsy, and a range... Agent: Banner & Witcoff, Ltd.

20070202159 - Pharmaceutical composition comprising stabilized statin particles: The present invention relates to stabilized statin particles and process for preparation thereof.... Agent: Ranbaxy Inc.

20070202160 - Solid-state form of celecoxib having enhanced bioavailability: The selective cyclooxygenase-2 inhibitory drug celecoxib is provided in amorphous form. Also provided is a celecoxib drug substance wherein the celecoxib is present, in at least a detectable amount, as amorphous celecoxib. Also provided is a celecoxib-crystallization inhibitor composite comprising particles of amorphous celecoxib or a celecoxib drug substance of... Agent: Pharmacia Corporation Global Patent Department

20070202161 - Pharmaceutical formulations: Capsule formulations are provided containing at least two different fill compositions which are prevented from mixing either by providing both of the fill compositions as solids or by providing a physical barrier which separates the fill compositions so that they are prevented from mixing. The invention has the advantage that... Agent: Leydig Voit & Mayer, Ltd

20070202162 - Extended release pharmaceutical compositions: The present invention relates to extended release pharmaceutical compositions comprising a beta-blocker drug or a pharmaceutically acceptable salt thereof, wherein said composition comprises at least two extended release portions, each portion having an in vitro dissolution profile that is different from another portion.... Agent: Dr. Reddy's Laboratories, Inc.

20070202164 - Andrographis extract formulations: A pharmaceutical formulation containing 50-90% by weight a powdered extract of Andrographis paniculata and 5-50% by weight a powdered blocking agent. The formulation may further contain a pore-forming agent, a filler, a lubricant, or a glidant. Also described are a method for preparing this pharmaceutical formulation and a method for... Agent: Occhiuti Rohlicek & Tsao, LLP

20070202163 - Fast-disintegrating epinephrine tablets for buccal or sublingual administration: Described herein are formulations for fast-disintegrating epinephrine tablets which can be prepared for buccal or sublingual administration, wherein the fast-disintegrating epinephrine tablets can produce plasma epinephrine concentrations substantially equivalent to those achieved by traditional injectable dosage forms comprising epinephrine injected either subcutaneously or intramuscularly.... Agent: Wilson Sonsini Goodrich & Rosati

20070202165 - Method for a supplemental dietary composition having a multi-phase dissolution profile: The present invention relates to a method and composition for achieving a multi-phasic dissolution prolife through the process of fine-milling to increase the rate of dissolution of ingredients. The ingredients to be fine-milled are ingredients suitable for use in supplemental dietary compositions.... Agent: Kenyon & Kenyon LLP

20070202166 - Method for increasing the rate and consistency of bioavailability of supplemental dietary ingredients: The present invention relates to a method for increasing the rate of bioavailability of orally administered supplemental dietary ingredients through the process of fine-milling to increase the rate of dissolution of the ingredients. The ingredients to be fine-milled are ingredients suitable for use in supplemental dietary compositions.... Agent: Kenyon & Kenyon LLP

20070202167 - Hyoscyamine dosage form: A pharmaceutical dosage form which comprises two or more different hyoscyamine formulations, at least one of the formulations being an immediate release hyoscyamine formulation and at least one other one being a controlled release hyoscyamine formulation. This abstract is neither intended to define the invention disclosed in this specification nor... Agent: Greenblum & Bernstein, P.L.C

20070202168 - Composition comprises sustained-release fine particles and manufacturing method thereof: The present invention relates to a composition comprising sustained-release fine particles, characterized in that it contains sustained-release fine particles that can be used in quick-disintegrating tablets in the buccal cavity, one or more fillers selected from the group consisting of sugars or sugar alcohols, and one or more binders for... Agent: Townsend And Townsend And Crew, LLP

20070202170 - Dual-release compositions of a cyclooxygenase-2 inhibitor: Pharmaceutical compositions are provided comprising one or more orally deliverable dose units, each comprising a selective cyclooxygenase-2 inhibitory drug of low water solubility, for example celecoxib, in an immediate-release fraction and a controlled-release, slow-release, programmed-release, timed-release, pulse-release, sustained-release or extended-release fraction. The compositions are useful in treatment or prophylaxis of... Agent: Pharmacia Corporation Global Patent Department

20070202169 - Lansoprazole orally disintegrating tablets: The invention provides orally disintegrating tablets that readily disintegrates in the mouth, releasing enteric coated drug sub-tablets.... Agent: Kenyon & Kenyon LLP

20070202171 - Method of producing a pharmaceutical composition: With the object of providing a method for producing a pharmaceutical composition comprising a drug-containing layer, a first functional layer provided to one side of the drug-containing layer either directly or via an intermediate layer, and a second functional layer provided to the other side of the drug-containing layer either... Agent: Posz Law Group, PLC

20070202172 - Metoprolol succinate e.r. tablets and methods for their preparation: The present invention provides extended release pharmaceutical compositions of a beta blocker such as, but not limited to, metoprolol succinate as the active ingredient and methods of preparing such extended release pharmaceutical compositions.... Agent: Kenyon & Kenyon LLP

20070202173 - Biodegradable, non-toxic biological adhesive for use in abdominal surgery: A biological adhesive formulation comprising dextrin, at least one adhesiveness modifier agent, and at least one antibiotic is suitable for promoting healing of tissue in a patient, for example, to prevent anastomosis of a surgical wound in the digestive system of a patient, and for affixing a prosthesis during a... Agent: Millen, White, Zelano & Branigan, P.C.

20070202174 - New mandelic acid derivatives and their use as thrombin inhibitors: There is provided a compound of formula (I) wherein Ra, R1, R2, Y and R3 have meanings given in the description and pharmaceutically-acceptable derivatives (including prodrugs) thereof, which compounds and derivatives are useful as, or are useful as prodrugs of, competitive inhibitors of trypsin-like proteases, such as thrombin, and thus,... Agent: Morgan Lewis & Bockius LLP

20070202175 - Pharmaceutical composition and process: The present invention relates to a pharmaceutical composition comprising a solid suspension prepared by hot melt extrusion of isobutyric acid (2R,3S,4R,5R)-5-(4-amino-2-oxo-2H-pyrimidin-1-yl)-2-azido-3,4-bis-iso-butyryloxy-tetrahydro-furan-2-ylmethyl ester; hydrochloride salt (I) and a polyethylene glycol (PEG)/polypropylene glycol (PPG) block copolymer.... Agent: Roche Palo Alto LLC Patent Law Dept. M/s A2-250

20070202177 - Antimicrobial compositions and methods for locking catheters: Antimicrobial compositions for use in locking catheters and other devices are provided. In some embodiments, the composition includes at least one alcohol, at least one biocidal agent which is not an alcohol, and one or more poloxamers; in other embodiments, the composition comprises at least one poloxamer and at least... Agent: David W. Highet, Vp And ChiefIPCounsel Becton Dickinson And Company

20070202176 - Bacteria support material: The present invention relates to a composite material made of non-metallic inorganic grains and plastics particles. The composite material is particularly suitable as a carrier material for bacteria for use in sewage treatment plants. It is characterized by a large surface suitable for the colonization of bacteria and also by... Agent: Lahive & Cockfield, LLP

20070202178 - Drug delivery matrices to enhance wound healing: Bioactive molecules are entrapped within a matrix for the controlled delivery of these compounds for therapeutic healing applications. The matrix may be formed of natural or synthetic compounds. The primary method of entrapment of the bioactive molecule is through precipitation of the bioactive molecule during gelation of the matrix, either... Agent: Patrea L. Pabst Pabst Patent Group LLP

20070202179 - Low dose pharmaceutical products: This invention relates to a method of formulating dosage forms of pharmaceutically active ingredients and to solid dosage forms produced thereby wherein the dosage form contains a very low dose, more especially an ultra-low dose of the pharmaceutically active ingredients.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20070202181 - Low hygroscopic aripipazole drug substance and processes for the preparation thereof: The present invention provides low hygroscopic forms of aripiprazole and processes for the preparation thereof which will not convert to a hydrate or lose their original solubility even when a medicinal preparation containing the aripiprazole anhydride crystals is stored for an extended period.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070202180 - Nanoparticulate carverdilol formulations: The present invention is directed to nanoparticulate carvedilol compositions having improved pharmacokinetic profiles, improved bioavailability, dissolution rates and efficacy. In one embodiment, the nanoparticulate carvedilol composition has an effective average particle size of less than about 2000 nm.... Agent: Elan Drug Delivery, Inc. C/o Foley & Lardner LLP

20070202186 - Apparatus and formulations for suprachoroidal drug delivery: Drug formulations, devices and methods are provided to deliver biologically active substances to the eye. The formulations are delivered into scleral tissues adjacent to or into the suprachoroidal space without damage to the underlying choroid. One class of formulations is provided wherein the formulation is localized in the suprachoroidal space... Agent: Beyer Weaver LLP

20070202183 - Composition and method for preparing alginate nanocapsules: The present invention discloses a method for preparing alginate nanocapsules, including the steps of: (a) forming a water-in-oil emulsion including an alginate in water, an oil, and at least one nonionic surfactant; and (b) separating the aqueous phase and oil phase to obtain the semisolid form alginate nanocapsules; and (c)... Agent: Anna Wu

20070202184 - Liquid compositions including microencapsulated delivery vehicles: Microencapsulated delivery vehicles comprising an active agent are disclosed. In one embodiment, the microencapsulated delivery vehicles are heat delivery vehicles capable of generating heat upon activation. The microencapsulated heat delivery vehicles may be introduced into wet wipes such that, upon activation, the wet wipe solution is warmed resulting in a... Agent: Senniger Powers (kcc)

20070202185 - Microencapsulated delivery vehicles having fugitive layers: Stabilized substantially fluid-impervious microencapsulated delivery vehicles comprising an active agent are disclosed. The microencapsulated delivery vehicles have improved rupture force strength. In one embodiment, the microencapsulated delivery vehicles are heat delivery vehicles capable of generating heat upon activation. The microencapsulated heat delivery vehicles may be introduced into wet wipes such... Agent: Senniger Powers (kcc)

20070202182 - Preparing solid formulation of nanoparticles of pharmaceutical ingredient, including at least micron-sized particles: A slurry is prepared in which nanoparticles of a pharmaceutical ingredient have been formed within a solvent. A solid formulation of the nanoparticles of the pharmaceutical ingredient is prepared from the slurry, without employing electrostatic collection. The solid formulation of the nanoparticles includes at least micron-sized particles.... Agent: Hewlett Packard Company

20070202187 - Dosage forms: Dosage forms comprising therapeutically active compounds are disclosed herein.... Agent: Allergan, Inc.

20070202188 - Use of alkene carboxlic acid n alkylamides as flavouring agents: s

20070202189 - Acellular bioabsorbable tissue regeneration matrices: The present invention provides methods and compositions useful in the regeneration of damaged, lost and/or degenerated tissue in humans and animals. In certain embodiments, the present invention provides an acellular bioabsorbable tissue regeneration matrix, methods of making such a matrix, and methods of using such a matrix for the regeneration... Agent: Choate, Hall & Stewart LLP Patent Department

20070202191 - Bone graft materials derived from mineralized gelatin: The present invention provides novel methods of forming mineralized gelatin carriers from bone. The present invention further provides mineralized gelatin carriers themselves; bone products that include such mineralized gelatin carriers including DBM bone products; and kits that include mineralized gelatin carriers formed from bone. The present invention further provides methods... Agent: Globus Medical, Inc. Attn: Brian Malm

20070202190 - Bone graft materials derived from mineralized gelatin: The present invention provides novel methods of forming mineralized gelatin carriers from bone. The present invention further provides mineralized gelatin carriers themselves; bone products that include such mineralized gelatin carriers including DBM bone products; and kits that include mineralized gelatin carriers formed from bone. The present invention further provides methods... Agent: Globus Medical, Inc. Attn: Brian Malm

20070202192 - Fungical mixtures for controlling rice pathogens: 2) phosphorous acid H3PO3, its alkali metal or alkaline earth metal salts or derivatives releasing them II in a synergistically effective amount, methods for controlling harmful fungi using mixtures of the compound I with the compound II, the use of the compound I with the compound II for preparing such... Agent: Birch Stewart Kolasch & Birch

20070202193 - Inhibition of reactive oxygen species and protection of mammalian cells: Methods and compositions useful for neuronal protection in retinal cells in vitro and the protection of mammalian cells from reactive oxygen species in vivo are provided. Ultrafine nano-size cerium oxide particles, less than 10 nanometers in diameter, have been provided to decrease reactive oxygen species (ROS) in retina tissue that... Agent: Law Offices Of Brian S Steinberger

20070202194 - Preparation for the prevention and/or treatment of vascular disorders: The present invention relates to a preparation suitable for the prevention and/or treatment of vascular disorders, comprising the following fractions: fraction a) consisting of long chain polyunsaturated fatty acids; fraction b) consisting of phospholipids, which fraction contains at least two different phospholipids selected from the group consisting of phosphatidylserine, phosphatidylinositol,... Agent: Foley And Lardner LLP Suite 500

20070202195 - Delivery of functional ingredients: The present invention relates to a primary composition comprising all essential nutrients of a fruit or a plant material, which has an increased stability, bio-availability and miscibility; and the process of forming the same. It also relates to an oral composition that contains the primary composition in a foodstuff, in... Agent: Bell, Boyd & Lloyd LLP

20070202197 - Pawpaw and/or peach derived composition: There is provided a process for making a composition suitable for topical application comprising the steps of a) heating at least one fruit and/or vegetable pulp to up to a temperature in the range of about 40° C. to 100° C.; b) mixing between 1 and 40% w/w of a... Agent: Viviana Amzei Ipac Consultants

20070202196 - Plant extract mixtures and their uses: A composition comprising extract of one or more plants of one or more of the following plant families: Cissus, Vernonia and Brillantasia. Such compositions have beneficial activity principally in controlling weight gain and obesity, especially in conjunction with chitosan or a chitosan derivative and an antioxidant such as vitamin C.... Agent: Greenberg Traurig LLP (la)

20070202198 - Process of obtaining thylakoids from photosynthetic organisms; plant fractions obtained from the process; pure thylakoids; and methods of use of thylakoids as ros scavengers, photo-protectors, biosensors biofilters and bioreactors: This invention relates to a process by which an extract comprising integral thylakoids is obtained. The resulting extract is a potent dynamic antioxidant useful as a ROS (reactive oxygen species) scavenger. This extract is intended to be used for the treatment or prevention of diseases involving the generation of ROS,... Agent: Godfrey & Kahn S.c.

20070202199 - Compositions for enhancing sexual responsiveness: A topical composition which enhances sexual responsiveness of a mammal is disclosed. An effective dosage of a peripheral vasodilator, an absorption enhancer and, optionally, a vasoconstrictor and an alpha receptor blocker are combined with a pharmaceutically-acceptable topical vehicle to produce the composition. The compositions are applied topically to the penis... Agent: Sheridan Ross PC

20070202200 - Method of inhibiting weight regain after weight loss: A composition for reducing the weight of a human. The composition is provided in the form of a capsule comprising an effective amount of capsaicin and/or analogs thereof, L-tyrosine, supplemental caffeine and/or and analogs thereof, green tea extract containing catechin and caffeine, and embodiments which include calcium. The invention is... Agent: Gordon & Rees LLP

20070202201 - Pharmaceutics of treaditiional chinese medicine of treating aids and preparation method thereof: The present invention provides a pharmaceutics of traditional Chinese medicine for treating AIDS and preparation method thereof, said pharmaceutics is prepared from Geranium, Root of Membranous Milkvetch, Herba Solani Nigri, Honeysuckle Flower, Flower of Common Bombax, Fruit of Belleric Terminalia, Herba Hedyotis Diffusae, Pomegranate Rind, Radix Oryzae, Fructus Trapae. The... Agent: J C Patents, Inc.

20070202203 - Anti-ageing composition: The invention relates to a composition containing, in a physiologically acceptable medium, at least: hyaluronic acid and/or one of its salts; at least one extract of soybean proteins; and at least one compound of formula (I) as described herein. This composition is useful for preventing and/or decreasing the signs of... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070202202 - Method for enhancing the content of soybean seed gamma-aminobutyric acid: The present invention relates to a display apparatus including a display part displaying a digital signal that includes a pixel clock, frequency adjusting part adjusting a frequency of the pixel clock, and a controller controlling the frequency adjusting part to adjust the frequency of the pixel clock of the digital... Agent: O'keefe, Egan, Peterman & Enders LLP

20070202204 - Plant extract mixtures and their uses: A composition comprising extract of one or more plants of one or more of the following plant families: Cissus, Vermonia and Brillantasia. Such compositions have beneficial activity principally in controlling light gain and obesity, especially in conjunction with chitosan or a chitosan derivative and an antioxidant such as vitamin C.... Agent: Greenberg Traurig LLP (la)

20070202205 - Carbohydrase inhibitors derived from chestnut and use thereof: The present invention provides a plant-derived carbohydrase inhibitor, wherein the inhibitor is effective for preventing or alleviating diabetes, or preventing obesity, and foods, drinks, and medicines containing the same. The present invention is accomplished by use of an α-amylase inhibitor or an α-glucosidase inhibitor as a carbohydrase inhibitor that is... Agent: Fitch, Even, Tabin & Flannery

20070202206 - Morinda citrifolia leaf juice and leaf extract based formulations: A method and composition for inhibiting certain enzymes, where such inhibition results in various health benefits is provided. More particularly, a method and composition using one or more of the following: Noni Leaf Extract; Noni Leaf Juice; and/or Roast Leaf to inhibit the following: HMG-CoA Reductase; Phosphodiesterases (3 and 4)... Agent: Kirton And Mcconkie

20070202207 - Use of naturally occurring epoxidised molecules from vernonia galamensis: Epoxidised oil, epoxidised wax or epoxidised fatty acid ester recovered from Vernonia Galamensis seeds provide topical medicament preparations which are effective in preventing and treating various different forms of skin diseases, skin lesions and wounds. These epoxidised oil, epoxidised wax or epoxidised fatty acid ester recovered from Vernonia Galamensis seeds... Agent: Koppel, Patrick & Heybl

20070202208 - Anti-inflammatory pharmaceutical compositions for reducing inflammation and the treatment or prevention of gastric toxicity: The invention provides hops (Humulus lupulus) extracts or derivatives thereof for use in treating a patient prophylactically and/or therapeutically for ulcerogenic-type disorders of the stomach and/or intestines. The ulcerogenic disorders can be of the type chemically induced, environmentally-induced, infection-induced, and/or stress-induced. The invention also provides a pharmaceutical composition comprising an... Agent: Mcdermott Will & Emery LLP

20070196273 - Oral dtpa for radionuclide chelation: A composition for oral radionuclide chelation therapy comprises a DTPA chelate selected from Zn-DTPA and Ca-DTPA and a permeation enhancer that preferentially increases jejunal uptake of the DTPA chelate. The composition has a DTPA chelate bioavailability of at least 10% of the chelate when orally administered to a mammal.... Agent: Richard Aron Osman

20070196288 - Method of treating periodontitis and of reducing dentinal sensitivity: An improved method of treating periodontitis includes the steps of: creating a formulation containing a lanthanide-containing protease inhibitor; and applying the formulation to a periodontal area. The lanthanide may be cerium chloride, samarium chloride, lutetium chloride, cerium chloride heptahydrate, lutetium chloride hexahydrate, samarium chloride hexahydrate, gadolinium, gadolinium nitrate, gadolinium chloride,... Agent: Phillips Lytle LLP Intellectual Property Group

20070196348 - Compositions and methods for the induction and maintenance of quality sleep: Supplemental compositions, and methods for administering same to a user, are provided for promoting a restful night's sleep by speedily inducing a person to fall asleep and to maintain sleep, as well as alleviating minor aches and pains so as to further improve the quality of a person sleep. The... Agent: Kenyon & Kenyon LLP

20070196271 - Compositions and methods related to serotonin 5-ht1a receptors: Contemplated substituted arylpiperazinyl compounds, and most preferably 18F-Mefway, exhibit desirable in vitro and in vivo binding characteristics to the 5-HT1A receptor. Among other advantageous parameters, contemplated compounds retain high binding affinity, display optimal lipophilicity, and are radiolabeled efficiently with 18F-fluorine in a single step. Still further, contemplated compounds exhibit high... Agent: Rutan & Tucker, LLP. Hani Z. Sayed

20070196270 - Compounds as ccri antagonists: n

20070196272 - Oral delivery of therapeutic agents using tight junction agonists: The present invention provides compositions and methods for the administration of the compositions to mammals. The compositions comprise therapeutic agents and an intestinal absorption enhancing amount of one or more tight junction agonists. Tight junction agonists include zonulin and/or ZOT receptor agonists. Methods of the invention include orally administering compositions... Agent: Connolly Bove Lodge Hutz, LLP (for Alba Therapeutics)

20070196269 - Pharmaceutical composition: The invention concerns a pharmaceutical composition comprising at least one stimulator of the immune cell functions and at least one substance inhibiting the cell proliferation and/or inducing cell death. In a preferred embodiment the stimulator of the function of the immune system and/or the immune cells are antagonists of TGF-beta... Agent: Jacobson Holman PLLC

20070196275 - Diagnostic imaging compositions, their methods of synthesis and use: Conjugate molecules comprising a ligand bonded to a polymer are disclosed. One such conjugate molecule comprises a ligand bonded to a polymer, a chelating agent bonded to the polymer, and a radioisotope chelated to the chelating agent. The conjugate molecules may be useful in detecting and/or treating tumors or biological... Agent: Lori Stiffler, Baker Botts L.L.P. One Shell Plaza

20070196274 - Immunoconjugates with improved efficacy for the treatment of diseases: The invention provides therapeutic or diagnostic antibodies with modified N— or C-terminal sequences that are enriched with lysine or tyrosine residues. These lysine or tyfosine residues can be used to couple radioisotopes, cytotoxic agents, or detectable labels. The increased stoichiometric ratios of these agents in the antibody conjugates lead to... Agent: Nixon Peabody, LLP

20070196276 - Monoclonal antibody ds6, tumor-associated antigen ca6, and methods of use thereof: The present application describes a monoclonal antibody selected from the group consisting of monoclonal antibody DS6, monoclonal antibodies that specifically bind to the antigen or epitope bound by